Harrow Health Inc
NASDAQ:HROW

Watchlist Manager
Harrow Health Inc Logo
Harrow Health Inc
NASDAQ:HROW
Watchlist
Price: 42.9 USD -2.23% Market Closed
Market Cap: 1.5B USD
Have any thoughts about
Harrow Health Inc?
Write Note

Harrow Health Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Harrow Health Inc
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Harrow Health Inc
NASDAQ:HROW
Revenue
$169.1m
CAGR 3-Years
36%
CAGR 5-Years
28%
CAGR 10-Years
65%
Johnson & Johnson
NYSE:JNJ
Revenue
$87.7B
CAGR 3-Years
-1%
CAGR 5-Years
1%
CAGR 10-Years
2%
Bristol-Myers Squibb Co
NYSE:BMY
Revenue
$47.4B
CAGR 3-Years
1%
CAGR 5-Years
14%
CAGR 10-Years
11%
Pfizer Inc
NYSE:PFE
Revenue
$60.1B
CAGR 3-Years
-4%
CAGR 5-Years
14%
CAGR 10-Years
2%
Merck & Co Inc
NYSE:MRK
Revenue
$63.2B
CAGR 3-Years
11%
CAGR 5-Years
7%
CAGR 10-Years
4%
Eli Lilly and Co
NYSE:LLY
Revenue
$40.9B
CAGR 3-Years
14%
CAGR 5-Years
13%
CAGR 10-Years
7%
No Stocks Found

Harrow Health Inc
Revenue Breakdown

Breakdown by Geography
Harrow Health Inc

Not Available

Breakdown by Segments
Harrow Health Inc

Total Revenue: 130.2m USD
100%
Product Sales Net: 117.4m USD
90.2%
Other Revenues: 12.7m USD
9.8%
Transfer Of Acquired Product Sales Profits: 12.7m USD
9.8%

Harrow Health Inc
Glance View

Market Cap
1.5B USD
Industry
Pharmaceuticals

Harrow Health, Inc. engages in the development, production, and sale of innovative medications. The company is headquartered in Nashville, Tennessee and currently employs 182 full-time employees. The company went IPO on 2013-02-08. The firm owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical business, and Visionology, a direct-to-consumer eye care subsidiary focused on chronic eye disease. The firm holds non-controlling equity positions in Eton Pharmaceuticals, Surface Ophthalmics and Melt Pharmaceuticals. The firm also owns royalty rights in four clinical stage drug candidates, which are being developed by Surface Ophthalmics and Melt Pharmaceuticals.

HROW Intrinsic Value
45.19 USD
Undervaluation 5%
Intrinsic Value
Price

See Also

What is Harrow Health Inc's Revenue?
Revenue
169.1m USD

Based on the financial report for Sep 30, 2024, Harrow Health Inc's Revenue amounts to 169.1m USD.

What is Harrow Health Inc's Revenue growth rate?
Revenue CAGR 10Y
65%

Over the last year, the Revenue growth was 48%. The average annual Revenue growth rates for Harrow Health Inc have been 36% over the past three years , 28% over the past five years , and 65% over the past ten years .

Back to Top